[关键词]
[摘要]
目的：评价半球后注射曲安奈德(triamcinolone acetonide，TA)治疗甲状腺相关眼病(thyroid associated ophthalmopathy，TAO)的临床效果。
方法：对46例84眼甲状腺相关眼病患者以TA 40mg加20g/L利多卡因0.5mL行眼部半球后注射，每3wk 1次，连续4次为1疗程，1，3，6mo随访观察，记录眼部症状、体征情况。
结果：患者43例自觉症状明显改善，眼球回退率83.6%，眼裂宽度缩小率85.2%，双眼视力改善率80.9%，眼球运动障碍、复视、斜视改善率80.5%。
结论：半球后注射TA治疗甲状腺相关眼病效果明显，不良反应小，安全可靠。
[Key word]
[Abstract]
AIM: To evaluate clinical effects of semiretrobulbar injection of triamcinolone acetonide(TA)for the treatment of thyroid associated ophalmopathy.
METHODS: Totally 84 eyes of 46 cases with thyroid associated ophalmopathy were treated with semiretrobulbar injection of TA(40mg)with 20g/L Lidocaine(0.5 mL)for each eye once every three weeks for four times during one course of treatment. Then symptoms and signs of the patients were observed after 1 month, 3 months, 6 mouths.
RESULTS: Symptoms of 43 cases were improved significantly. In all cases, eyeball recession rate was 83.6%, the palpebral fissure width reduction was 85.2%, visual acuity improvement was 80.9%, eye movement, strabismus, and diplopia improvement was 80.5%, compared to those before the treatment.
CONCLUSION: The treatment of semiretrobulbar injection of TA for thyroid associated ophalmopathy is safe, effective and mild in side effect.
[中图分类号]
[基金项目]
